NCT03488420View on ClinicalTrials.gov

Canadian EdoxAban(Lixiana®) Registry in Patients With ATrial Fibrillation/Flutter With Confirmed ValvUlar HeaRt DiseasE

CompletedOBSERVATIONAL
Enrollment

136

Participants

Timeline

Start Date

April 30, 2019

Primary Completion Date

March 21, 2025

Study Completion Date

April 3, 2025

Conditions
Atrial Fibrillation and FlutterValvular Heart Disease
Interventions
DRUG

Edoxaban Pill

Subjects will be taking edoxaban 30 or 60 mg

Trial Locations (9)

Unknown

CIUSSS de l'Estrie-CHUS-Centre Haute-Yamaska-hôpital de Granby, Granby

CISSS de la Montérégie Centre, Greenfield Park

CISSS de Laval, Laval

IUCPQ, Québec

CISSS du Bas-Saint-Laurent/Hôpital Régional de Rimouski, Rimouski

Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke

CIUSSS de la Mauricie-et-du-Centre-du-Québec, Trois-Rivières

H1T 1C8

Montreal Heart Institute, Montreal

G5Y 4T8

CISSS de Chaudière-Appalaches - Hopital Saint-Georges, Saint-Georges

All Listed Sponsors
collaborator

Servier

INDUSTRY

lead

Montreal Heart Institute

OTHER

NCT03488420 - Canadian EdoxAban(Lixiana®) Registry in Patients With ATrial Fibrillation/Flutter With Confirmed ValvUlar HeaRt DiseasE | Biotech Hunter | Biotech Hunter